Effects of vigabatrin on the GABAergic system as determined by [123I]iomazenil SPECT and GABA MRS

Epilepsia

Volumn 40, Issue 10, 1999, Pages 1433-1438

  Verhoeff, Nicolaas Paul L G ^a,c   Petroff, Ognen A C ^a   Hyder, Fahmeed ^a   Zoghbi, Sami S ^a   Fujita, Masahiro ^a   Rajeevan, Nallakkandi ^a   Rothman, Douglas L ^a   Seibyl, John P ^a   Mattson, Richard H ^a,b   Innis, Robert B ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^c YALE UNIVERSITY   (United States)

Author keywords

Benzodiazepine receptor; GABA; MRS; SPECT; Vigabatrin

Indexed keywords

4 AMINOBUTYRIC ACID; BENZODIAZEPINE RECEPTOR; IOMAZENIL; VIGABATRIN;

4 AMINOBUTYRIC ACID BRAIN LEVEL; ADULT; ANTICONVULSANT ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FOCAL EPILEPSY; GABAERGIC SYSTEM; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OCCIPITAL CORTEX; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RECEPTOR DENSITY; RECEPTOR DOWN REGULATION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ADULT; ANTICONVULSANTS; FEMALE; FLUMAZENIL; HUMANS; IODINE RADIOISOTOPES; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; OCCIPITAL LOBE; RECEPTORS, GABA; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; VIGABATRIN;

EID: 0032879876     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.1999.tb02016.x     Document Type: Article

References (37)

1. Jung MJ, Palfreyman MG. Vigabatrin: mechanisms of action. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995:903-13.
2. Schousboe A, Larsson OM, Seiler N. Stereoselective uptake of the GABA-transaminase inhibitors gamma-vinyl GABA and gamma- acetylenic GABA into neurons and astrocytes. Neurochem Res 1986;11:1497-505.
3. Petroff OAC, Rothman DL, Behar KL, Mattson RH. Human brain GABA levels rise after initiation of vigabatrin therapy but fail to rise further with increasing dose. Neurology 1996;46:1459-63.
4. Schlechter PJ, Hanke NFJ, Grove J, Huebert N, Sjoerdsma A. Biochemical and clinical effects of gamma-vinyl-GABA in patients with epilepsy. Neurology 1984;34:182-6.
5. Ben-Menachem E, Persson LI, Schechter PJ, et al. The effect of different vigabatrin treatment regimens on CSF biochemistry and seizure control in epileptic patients. Br J Clin Pharmacol 1989;27 (suppl 1):79S-85S.
6. Ben-Menachem E, Persson LI, Mumford JP, Haegele KD, Huebert N. The effect of long-term vigenetrin therapy on selected neurotransmitter concentrations in cerebrospinal fluid. J Child Neurol 1991;6(suppl 2):2S11-6.
7. Reikkinen PJ, Ylinen A, Halonen T, Sivenius J, Pitkänen A. Cerebrospinal fluid GABA and seizure control with vigabatrin. Br J Clin Pharmacol 1989;27(suppl 1):87S-94S.
8. Kälviäinen R, Halonen T, Pitkänen A, Reikkinen PJ. Amino acid levels in the cerebrospinal fluid of newly diagnosed epileptic patients: effect of vigabatrin and carbamazepine monotherapies. J Neurochem 1993;60:1244-50.
9. A receptors. Int Rev Neurobiol 1996;39:53-76.
10. A receptor subunit polypeptides increase in parallel but exhibit distinct distributions in the developing rat cerebellum. J Neurobiol 1994;25:1533-44.
11. Belhage B, Hansen GH, Meier E, Schoesboe A. Effects of inhibitors of protein synthesis and intracellular transport on the GABA-agonist induced functional differentiation of cultured cerebellar granule cells. J Neurochem 1990;55:1107-13.
12. A receptor mRNAs and increases ligand binding. J Neurochem 1993; 61:2334-7.
13. Schmid L, Bottlaender M, Brouillet E, Fuseau C, Mazière M. Vigabatrin modulates benzodiazepine activity in vivo: a positron emission tomography study in baboon. J Pharmacol Exp Ther 1996;276:977-83.
14. Weber OM, Verhagen A, Due CO, Meier D, Leenders KL, Boesiger P. Effects of vigabatrin on GABA-ergic cycle as determined by MRS and PET [Abstract] Physics Biol Med 1997;5 (suppl):67.
15. 11C]flumazenil and positron emission tomography. Epilepsia 1995;36:113-21.
16. McLean MJ, MacDonald RL. Sodium valproate, but not ethosuximide, produces use- and voltage-dependent limitation of high frequency repetitive firing of action potentials of mouse central neurons in cell culture. J Pharmacol Exp Ther 1986;237:1001-11.
17. Schechter PJ, Tranier Y, Grove J. Effect of n-dipropylacetate on amino acid concentrations in mouse brain: correlation with anticonvulsant activity. J Neurochem 1987;31:1325-7.
18. Gram L, Larsson OM, Johnsen AH, et al. Effects of valproate, vigabatrin and aminooxyacetic acid on release of endogenous and exogenous GABA from cultured neurons. Epilepsy Res 1988;2: 87-95.
19. Schubiger PA, Hasler PH, Beer-Wohlfahrt H, et al. Evaluation of a multicentre study with iomazenil: a benzodiazepine receptor ligand. Nucl Med Commun 1991;12:569-82.
20. 123I]iomazenil binding to benzodiazepine receptors in nonhuman primates: II. Equilibrium analysis of constant infusion experiments and correlation with in vitro parameters. J Cereb Blood Flow Metab 1994;14:453-65.
21. 123I]iomazenil: kinetic and equilibrium paradigms. J Nucl Med 1994;35:228-38.
22. 1H NMR measurements of gamma-aminobutyric acid in human brain in vivo. Proc Natl Acad Sci USA 1993;90:5662-6.
23. 123I]iomazenil in human and nonhuman primates. Nucl Med Biol 1992;19:5.
24. Friston KJ, Ashburner J, Poline JB, Frith CD, Heather JD, Frackowiak RSL. Spatial registration and normalisation of images. Hum Brain Mapp 1995;22:165-89.
25. Rajeevan N, Zubal IG, Ramsby SQ, Zoghbi SS, Seibyl JP, Innis RB. Significance of nonuniform attenuation correction in quantitative brain SPECT imaging. J Nucl Med 1998;39:1719-26.
26. Fujita M, Verhoeff NPLG, Baldwin RM, et al. Reproducibility of [I-123]iomazenil equilibrium measurement of benzodiazepine receptors [Abstract]. J Nucl Med 1998;208P.
27. Frey KA, Minoshima S, Koeppe RA, Kilbourn MR, Berger KL, Kuhl DE. Stereotaxic summation analysis of human cerebral benzodiazepine binding maps. J Cereb Blood Flow Metab 1996;16: 409-17.
28. Koepp MJ, Richardson MP, Brooks DJ, et al. Cerebral benzodiazepine receptors in hippocampal sclerosis. Brain 1996;119:1677-87.
29. 11C-flumazenil PET, volumetric MRI, and quantitative pathology in mesial temporal lobe epilepsy. Neurology 1997;49:764-73.
30. 11C-flumazenil PET study. An Neurol 1996;40:188-98.
31. Maloteaux JM, Octave JN, Gossuin A, Laterre C, Trouet A. GABA induces down-regulation of the benzodiazepine-GABA receptor complex in the rat cultured neurons. Eur J Pharmacol 1987;144: 173-83.
32. Fujita M, Woods SW, Verhoeff NPLG, et al. Changes of benzodiazepine receptors during chronic benzodiazepine administration in humans Eur J Pharmacol 1999;368:161-72.
33. Machin D, Campbell MJ. Statistical tables for the design of clinical trials. Oxford, England: Blackwell Scientific Publications, 1987.
34. Houston AS, Kemp PM, Macleod MA. A method for assessing the significance of abnormalities in HMPAO brain SPECT images. J Nucl Med 1994;35:239-44.
35. Abi-Dargham A, Lamelle M, Krystal J, et al. No evidence of altered in vivo benzodiazepine receptor binding in schizophrenia. Neuropsychopharmacology 1999;20:650-61.
36. 11C-diprenorphine binding in Huntington's disease: a comparison of region of interest analysis with statistical parametric mapping. J Cereb Blood Flow Metab 1997;17:943-9.
37. Wright IC, Ellison ZR, Sharma T, Friston KJ, Murray RM, McGuire PK. Mapping of grey matter changes in schizophrenia. Schizophr Res 1999;35:1-14.